Yahoo Web Search

  1. Ads
    related to Leukemia
  1. Yahoo Finance Results

  2. Two clinical trial sites are currently screening and enrolling patients and five additional sites are planned to be activated by the end of the first quarter. PCM-075 is the first oral PLK1- ...

  3. Here's What Pfizer's Saying About Its Future

    Motley Fool via Yahoo FinanceFeb 02 15:10 PM

    Pfizer Inc.'s (NYSE: PFE) fourth-quarter and full-year 2017 financial results suggest it's on its way toward becoming a growth stock again, and on its quarterly conference call, management unveiled ...

  4. View the full release here: http://www.businesswire.com/news/home/20180203005067/en/ Andrew, who has been battling leukemia since 2015, received an “Imagine Me” bedroom makeover through ...

  5. Sales of Eliquis were $1.36 billion during the reported quarter, up 44% year over year. Multiple myeloma drug, Empliciti recorded sales of $63 million, up 34% year over year. Research and development ...

  6. Top Research Reports for Novartis, BP & Biogen

    Zacks via Yahoo FinanceFeb 08 20:23 PM

    Thursday, February 8, 2018 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including ...

  7. Why Agios Pharmaceuticals Shares Jumped 37.8% in January

    Motley Fool via Yahoo FinanceFeb 07 17:57 PM

    After filing for FDA approval of its second drug in acute myeloid leukemia (AML) and updating investors on its plans at the J.P. Morgan healthcare conference, shares in Agios Pharmaceuticals ...

  8. Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?

    Zacks via Yahoo FinanceFeb 09 16:20 PM

    Agios Pharmaceuticals, Inc. AGIO is scheduled to report fourth-quarter and full year 2017 results on Feb 14, before the opening bell. Overall, Agios has an average beat of 4.48%.

  9. We expect ImmunoGen, Inc. IMGN to beat estimates when it reports fourth-quarter 2017 results on Feb 9 before the market opens. Last quarter, the company delivered a negative earnings surprise ...

  10. Forty Seven Inc. a clinical-stage company focused on developing the next generation of transformational immuno-oncology treatments to enable patient's immune systems to defeat their cancer, ...

  11. 3 Boom-or-Bust Biotech Stocks to Buy in 2018

    Motley Fool via Yahoo FinanceFeb 04 13:01 PM

    Can Summit Therapeutics (NASDAQ: SMMT), Jounce Therapeutics (NASDAQ: JNCE), and TG Therapeutics (NASDAQ: TGTX) overcome the odds of clinical trial failure? All three are high-risk clinical-stage ...

  1. Ads
    related to Leukemia